ISO 9001:2015 Certified WHO-GMP PCD Pharma Franchise Company in India300+ Products Monopoly Rights Pan India DistributionCall us: +91-86533 91199

Product List

Home / ARPOD-CV DRY SYP

DJ-6

Product Packing: 10X10

Product Composition: Deflazacort 6 mg

Product Price: MRP : 1406.25

DJ-6 Tablets

Deflazacort 6 mg Tablets

DJ-6 is a prescription corticosteroid formulation containing Deflazacort 6 mg. Deflazacort has glucocorticoid activity and may be prescribed for selected inflammatory, allergic or immune-mediated conditions where systemic corticosteroid therapy is clinically appropriate.

Deflazacort modifies inflammatory and immune responses through glucocorticoid receptor-mediated effects. Because systemic corticosteroids can produce important adverse effects, treatment should be individualized and used strictly according to the approved product label and qualified medical advice.

Composition

Each tablet contains:

· Deflazacort - 6 mg

· Excipients - q.s.

Dosage form: Tablet

Pack size: 10 x 10 tablets

Uses of DJ-6

DJ-6 may be prescribed for selected conditions requiring systemic corticosteroid therapy, depending on the approved indication and individual clinical assessment.

· Management of selected inflammatory conditions

· Management of selected allergic conditions where systemic corticosteroid treatment is indicated

· Management of selected immune-mediated disorders under medical supervision

· Other approved corticosteroid-responsive conditions as determined by the prescribing clinician

Deflazacort should not be used for self-treatment. The underlying condition, dose and treatment duration require professional medical assessment.

How DJ-6 Works

DJ-6 contains Deflazacort, a glucocorticoid corticosteroid:

Glucocorticoid receptor action: Deflazacort acts through intracellular glucocorticoid receptors and influences the expression of mediators involved in inflammation and immune responses.

Anti-inflammatory effect: It reduces production and activity of multiple inflammatory mediators.

Immunomodulatory effect: It can suppress selected immune responses when clinically required.

Systemic corticosteroid effects depend on dose, treatment duration and individual patient factors.

Dose selection, duration and any dose reduction or tapering must follow the approved product label and prescribing clinician's advice.

Dosage and Direction for Use

Use DJ-6 exactly as prescribed. The dose varies substantially according to the condition being treated, severity, patient response, age and other clinical factors.

Take the tablet at the time and frequency directed by the prescriber. Administration with food may help reduce stomach discomfort in some patients.

Do not increase, reduce or stop the medicine on your own.

After prolonged or sufficiently intensive corticosteroid treatment, abrupt discontinuation can be unsafe. Dose reduction or tapering should be directed by a healthcare professional.

Possible Side Effects

Possible unwanted effects may include:

· Increased appetite, indigestion, stomach discomfort, headache or mood changes

· Fluid retention, increased blood pressure, increased blood glucose or weight gain

· Sleep disturbance, mood or behavioral changes and, less commonly, more serious psychiatric effects

· Longer or higher-dose therapy can increase risks such as infection, adrenal suppression, osteoporosis, muscle weakness, eye problems and metabolic effects

· Seek prompt medical attention for severe infection symptoms, vision changes, unusual swelling, severe mood changes, gastrointestinal bleeding or other serious symptoms.

Adverse-effect risk generally increases with higher doses and longer treatment duration.

Precautions and Contraindications

Before using DJ-6, the prescriber should review infection risk, vaccination status, diabetes, blood pressure, gastrointestinal, bone, eye, liver and other relevant medical conditions. Important precautions include:

· Do not use in patients with known hypersensitivity to Deflazacort or formulation ingredients.

· Systemic corticosteroids can suppress immune responses and may increase susceptibility to infection or mask signs of infection. Active or latent infections require careful medical assessment.

· Long-term therapy may suppress the hypothalamic-pituitary-adrenal axis; abrupt withdrawal after prolonged treatment should be avoided.

· Use caution in patients with diabetes, hypertension, osteoporosis, peptic ulcer disease, glaucoma, cataract, psychiatric history or other conditions that corticosteroids may worsen.

· Live vaccines may be inappropriate during immunosuppressive corticosteroid therapy. Vaccination decisions should be discussed with the treating clinician.

· Pregnancy, breastfeeding, children, older adults and patients requiring prolonged treatment need individualized medical assessment and monitoring.

· Keep out of reach of children and store according to the approved pack instructions.

· Drug Interaction Considerations

· Deflazacort may interact with medicines that affect corticosteroid metabolism and with drugs such as certain anticonvulsants, anti-infectives, anticoagulants, diuretics, glucose-lowering medicines, NSAIDs and immunosuppressive therapies. Interaction relevance varies by medicine and patient.

· Patients should provide the prescriber with a complete list of prescription medicines, OTC products, vaccines and supplements before starting or changing corticosteroid therapy.

Business Growth Opportunity with DJ-6

DJ-6 offers pharmaceutical distributors and healthcare entrepreneurs an opportunity to add a Deflazacort 6 mg prescription corticosteroid tablet to their product portfolio.

Corticosteroid therapy is used across multiple medically supervised specialties. Promotion should remain strictly consistent with approved product information, prescription status and applicable pharmaceutical regulations.

Key Business Advantages

· Single-ingredient corticosteroid formulation

· Deflazacort 6 mg

· Established glucocorticoid corticosteroid molecule

· Convenient tablet dosage form

· Suitable addition to medically supervised prescription portfolios

· Opportunity for ethical promotion through appropriate healthcare channels

PCD Pharma Franchise Opportunity for DJ-6

Ethics Medinova Private Limited offers PCD Pharma Franchise opportunities for DJ-6 in selected territories across India, subject to availability, applicable regulations and mutually agreed business terms.

Franchise partners may benefit from the company's product portfolio, promotional support, supply coordination and business assistance.

Franchise Support May Include

· Monopoly-based territory opportunities, subject to availability

· Promotional materials and visual aids

· Product information and marketing support

· Reliable supply coordination

· Access to a growing pharmaceutical product portfolio

· Professional partner assistance

Partner with Ethics Medinova to explore PCD Pharma Franchise opportunities for DJ-6 and other quality-focused healthcare products.

Third-Party Manufacturing Support for Deflazacort 6 mg Tablets

Ethics Medinova also supports eligible businesses exploring third-party manufacturing of formulations similar to DJ-6 under their own brand, subject to applicable licensing, prescription-drug, regulatory and manufacturing requirements.

Our third-party manufacturing support may include:

· Customized product and pack requirements, subject to regulatory feasibility

· Private-label manufacturing opportunities

· Customized packaging and branding support

· Product label and pack configuration assistance

· Manufacturing coordination through suitable licensed facilities

· Support for documentation and applicable regulatory requirements

This service may be suitable for eligible pharmaceutical companies and healthcare brands seeking to expand a medically supervised prescription product portfolio.

Frequently Asked Questions About DJ-6

1. What is DJ-6?

DJ-6 is a tablet formulation containing Deflazacort 6 mg.

2. What is DJ-6 used for?

It may be prescribed for selected inflammatory, allergic or immune-mediated conditions where systemic corticosteroid therapy is clinically appropriate and approved.

3. How should DJ-6 be taken?

Take DJ-6 exactly as prescribed by a qualified healthcare professional. The dose and duration vary according to the condition and individual patient factors.

4. Can DJ-6 be stopped suddenly?

Abrupt discontinuation can be unsafe after prolonged or sufficiently intensive corticosteroid therapy. Any dose reduction or tapering should be directed by the prescriber.

5. Can Deflazacort increase infection risk?

Yes. Systemic corticosteroids can suppress immune responses and may increase susceptibility to infection or mask infection symptoms, especially with higher doses or longer treatment.

6. Does long-term treatment require monitoring?

Yes. Depending on dose and duration, monitoring may include blood pressure, blood glucose, bone health, eyes, infection risk and other clinically relevant parameters.

7. Is a PCD Pharma Franchise available for DJ-6?

Yes. Ethics Medinova offers PCD Pharma Franchise opportunities for selected products and territories, subject to availability, applicable regulations and mutually agreed terms.

8. Can this formulation be manufactured under my own brand?

Eligible businesses interested in a similar Deflazacort 6 mg tablet may explore third-party manufacturing and private-label support with Ethics Medinova, subject to applicable licensing and regulatory requirements.

Disclaimer

DJ-6 product information in this document is for general professional and business information. Exact approved indications, dosage, contraindications, warnings, interactions, tapering requirements, monitoring, duration of use, excipients and regulatory status must be verified against the current approved product label and applicable prescribing information before prescribing, dispensing, use or promotion. Systemic corticosteroids require medical supervision. This document is not a substitute for professional medical advice.

Dosage Form

Therapy Wise

DJ-6

DJ-6 Tablets

Deflazacort 6 mg Tablets

Composition

Pack size: 10 x 10 tablets

Deflazacort should not be used for self-treatment. The underlying condition, dose and treatment duration require professional medical assessment.

Immunomodulatory effect: It can suppress selected immune responses when clinically required.

Do not increase, reduce or stop the medicine on your own.

· Seek prompt medical attention for severe infection symptoms, vision changes, unusual swelling, severe mood changes, gastrointestinal bleeding or other serious symptoms.

· Keep out of reach of children and store according to the approved pack instructions.

· Patients should provide the prescriber with a complete list of prescription medicines, OTC products, vaccines and supplements before starting or changing corticosteroid therapy.

Corticosteroid therapy is used across multiple medically supervised specialties. Promotion should remain strictly consistent with approved product information, prescription status and applicable pharmaceutical regulations.

· Opportunity for ethical promotion through appropriate healthcare channels

Franchise partners may benefit from the company's product portfolio, promotional support, supply coordination and business assistance.

Partner with Ethics Medinova to explore PCD Pharma Franchise opportunities for DJ-6 and other quality-focused healthcare products.

This service may be suitable for eligible pharmaceutical companies and healthcare brands seeking to expand a medically supervised prescription product portfolio.

Frequently Asked Questions About DJ-6

DJ-6 is a tablet formulation containing Deflazacort 6 mg.

It may be prescribed for selected inflammatory, allergic or immune-mediated conditions where systemic corticosteroid therapy is clinically appropriate and approved.

Take DJ-6 exactly as prescribed by a qualified healthcare professional. The dose and duration vary according to the condition and individual patient factors.

Abrupt discontinuation can be unsafe after prolonged or sufficiently intensive corticosteroid therapy. Any dose reduction or tapering should be directed by the prescriber.

Yes. Systemic corticosteroids can suppress immune responses and may increase susceptibility to infection or mask infection symptoms, especially with higher doses or longer treatment.

Yes. Depending on dose and duration, monitoring may include blood pressure, blood glucose, bone health, eyes, infection risk and other clinically relevant parameters.

Yes. Ethics Medinova offers PCD Pharma Franchise opportunities for selected products and territories, subject to availability, applicable regulations and mutually agreed terms.

Eligible businesses interested in a similar Deflazacort 6 mg tablet may explore third-party manufacturing and private-label support with Ethics Medinova, subject to applicable licensing and regulatory requirements.

Address

Email

Phone

Dosage Form

Therapy Wise

DJ-6

DJ-6 Tablets

Deflazacort 6 mg Tablets

Composition

Pack size: 10 x 10 tablets

Deflazacort should not be used for self-treatment. The underlying condition, dose and treatment duration require professional medical assessment.

Immunomodulatory effect: It can suppress selected immune responses when clinically required.

Do not increase, reduce or stop the medicine on your own.

· Seek prompt medical attention for severe infection symptoms, vision changes, unusual swelling, severe mood changes, gastrointestinal bleeding or other serious symptoms.

· Keep out of reach of children and store according to the approved pack instructions.

· Patients should provide the prescriber with a complete list of prescription medicines, OTC products, vaccines and supplements before starting or changing corticosteroid therapy.

Corticosteroid therapy is used across multiple medically supervised specialties. Promotion should remain strictly consistent with approved product information, prescription status and applicable pharmaceutical regulations.

· Opportunity for ethical promotion through appropriate healthcare channels

Franchise partners may benefit from the company's product portfolio, promotional support, supply coordination and business assistance.

Partner with Ethics Medinova to explore PCD Pharma Franchise opportunities for DJ-6 and other quality-focused healthcare products.

This service may be suitable for eligible pharmaceutical companies and healthcare brands seeking to expand a medically supervised prescription product portfolio.

Frequently Asked Questions About DJ-6

DJ-6 is a tablet formulation containing Deflazacort 6 mg.

It may be prescribed for selected inflammatory, allergic or immune-mediated conditions where systemic corticosteroid therapy is clinically appropriate and approved.

Take DJ-6 exactly as prescribed by a qualified healthcare professional. The dose and duration vary according to the condition and individual patient factors.

Abrupt discontinuation can be unsafe after prolonged or sufficiently intensive corticosteroid therapy. Any dose reduction or tapering should be directed by the prescriber.

Yes. Systemic corticosteroids can suppress immune responses and may increase susceptibility to infection or mask infection symptoms, especially with higher doses or longer treatment.

Yes. Depending on dose and duration, monitoring may include blood pressure, blood glucose, bone health, eyes, infection risk and other clinically relevant parameters.

Yes. Ethics Medinova offers PCD Pharma Franchise opportunities for selected products and territories, subject to availability, applicable regulations and mutually agreed terms.

Eligible businesses interested in a similar Deflazacort 6 mg tablet may explore third-party manufacturing and private-label support with Ethics Medinova, subject to applicable licensing and regulatory requirements.

We value your privacy

Get the Product Details